Members of the board of directors and executive management subscribe in ongoing rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Biosergen AB (publ) (“Biosergen” or the “Company”) announces that CEO Peder Andersen, CFO Niels Laursen and board members Mattias Klintemar and Henrik Moltke are subscribing for a combined 58,522 units to a total value of 877,828 SEK in the ongoing rights issue of units (the “Rights Issue”).

Subscription and underwriting commitments
The Rights Issue is covered to approximately 33 percent through subscription commitments and to approximately 37 percent through underwriting commitments. In total, 70 percent of the Rights Issue is thus covered by subscription commitments and underwriting commitments.

Shares covered by lock up agreements
In addition to the subscriptions from board and management members, in accordance to previously communicated, Östersjöstiftelsen, Rosetta Capital and CEO Peder Andersen have entered lock up agreements that prevents them from selling any shares or related securities in Biosergen during a period of 12 months. In total, approximately 79 percent of the outstanding shares in the Company are covered by lock up agreements.

Shareholder letter available on website
For information on how to subscribe in the Rights Issue and a few summarizing words from CEO Peder Andersen, please see the shareholder letter published on www.biosergen.net or  https://emission.mangold.se/.